Matinas BioPharma Holdings Inc (MTNB) Sees Significant Decline in Short Interest
Matinas BioPharma Holdings Inc (NYSE:MTNB) saw a significant decrease in short interest during the month of September. As of September 29th, there was short interest totalling 2,182,518 shares, a decrease of 6.5% from the September 15th total of 2,334,686 shares. Approximately 3.1% of the company’s stock are sold short. Based on an average daily volume of 187,740 shares, the short-interest ratio is currently 11.6 days.
Matinas BioPharma Holdings (MTNB) opened at 1.36 on Wednesday. The firm has a 50-day moving average of $1.31 and a 200 day moving average of $2.01. Matinas BioPharma Holdings has a 52 week low of $1.01 and a 52 week high of $3.99. The stock’s market capitalization is $125.08 million.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/matinas-biopharma-holdings-inc-mtnb-sees-significant-decline-in-short-interest.html.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.